Is the Biotech Party Over?

I ran into an interesting article just as my EuroBio 'party' came to an end... John Simons of Fortune recently reported that while biotech has led a charmed existence in the U.S. due to the complexity of its products, Congress and FDA are under pressure to create inexpensive biosimilars. The European Commission seems to have already created a marketplace for generic biotech drugs. Last year, Novartis became the first company to gain approval (from the European Commission) to market a biosimilar - the human growth hormone, Omnitrope. The drug was later approved by the FDA upon special review. Will Biotech follow Big Pharma in fighting to compete against generics? For the full story click here. MV
Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.

Comments

  • <p>Dear MV:</p> <p>John Rhodes works for Deloitte. He is the Pharma Partner. John Simons wrote the article. Sorry for picking on you.</p> <p>Biosimilar fight has just started. Europeans are ahead in the biosimilar generic curve. Novartis had to challenge USFDA to get the approval. With the new onslaught from other players, US companies have two choices. Create regulatory roadblock or create new bio-entities. We have to remember that every "specialty" eventually becomes "commodity". Wmay be the cycle has started. Laws of economics will finally dictate the landscape and they will prevent the road blocks.</p>

    Reply

RSS feed for comments on this page | RSS feed for all comments